Key result
P2Y12 inhibitor monotherapy after short DAPT cuts MACCE ~11% and lowers bleeding risk post-DES.
Why the study?
Does P2Y12 inhibitor monotherapy after shorter-duration of DAPT reduce MACCE and bleeding in patients undergoing coronary DES implantation?
Meta-Analysis
Does P2Y12 inhibitor monotherapy after shorter-duration of DAPT reduce MACCE and bleeding in patients undergoing coronary DES implantation?
P2Y12 inhibitor monotherapy following a shortened duration of DAPT significantly reduces both ischemic (MACCE) and bleeding events in patients receiving coronary drug-eluting stents.
Answers are grounded in this paper and cite their sources.
Supports P2Y12 monotherapy after short DAPT post-DES to lower MACCE and bleeding; extends randomized trial evidence.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2022) conducted a meta-analysis in coronary drug-eluting stents implantation. P2Y12 inhibitor monotherapy after shorter-duration of DAPT was evaluated on composite of all-cause death, myocardial infarction (MI) and stroke (MACCE) (OR 0.89, 95% CI 0.79-0.99, p=0.037). P2Y12 inhibitor monotherapy after shorter-duration DAPT reduced MACCE and bleeding risk in patients undergoing coronary DES implantation.
Synapse has enriched 10 related papers. Consider them for comparative context: